Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sodium carboxymethyl starch solution is an oral immunomodulatory medication manufactured by Guangxi Nanning Baihui Pharmaceutical. While sodium carboxymethyl starch is widely recognized in the pharmaceutical industry as a disintegrant excipient for solid dosage forms, this specific aqueous solution is approved in China as a therapeutic agent. It is primarily indicated for the prevention and treatment of recurrent respiratory tract infections in pediatric patients and for the management of leukopenia caused by various factors. The drug is thought to enhance non-specific immune function and improve resistance to viral and bacterial pathogens. It is also occasionally utilized in the treatment of simple dyspepsia in children.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Sodium carboxymethyl starch solution.